CAMP cGMP PDE NO
(Die Seite wurde neu angelegt: „ '''Nitric oxide''' {{tp|p=32526061|t=2020. Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection.|pdf=|usr=008}} {{tp|p=32387333|t=ä. Could nasal nitric o…“) |
|||
| Zeile 5: | Zeile 5: | ||
{{tp|p=32436029|t=2020. Nitric oxide inhalation as an interventional rescue therapy for COVID-19-induced acute respiratory distress syndrome.|pdf=|usr=008}} | {{tp|p=32436029|t=2020. Nitric oxide inhalation as an interventional rescue therapy for COVID-19-induced acute respiratory distress syndrome.|pdf=|usr=008}} | ||
{{tp|p=32454510|t=2020. Potential Immunoregulatory and Antiviral/SARS-CoV-2 Activities of Nitric Oxide.|pdf=|usr=007}} | {{tp|p=32454510|t=2020. Potential Immunoregulatory and Antiviral/SARS-CoV-2 Activities of Nitric Oxide.|pdf=|usr=007}} | ||
| + | {{tp|p=32579020|t=2020. Treatment of COVID-19 by Inhaled NO to Reduce Shunt?|pdf=|usr=010}} | ||
| + | |||
'''PDE4 Inhibitors''' | '''PDE4 Inhibitors''' | ||
Version vom 8. Juli 2020, 08:51 Uhr
Nitric oxide
32526061 2020. Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection.
32387333 ä. Could nasal nitric oxide help to mitigate the severity of COVID-19?
32436029 2020. Nitric oxide inhalation as an interventional rescue therapy for COVID-19-induced acute respiratory distress syndrome.
32454510 2020. Potential Immunoregulatory and Antiviral/SARS-CoV-2 Activities of Nitric Oxide.
32579020 2020. Treatment of COVID-19 by Inhaled NO to Reduce Shunt?
PDE4 Inhibitors
32497535 2020. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.
PDE5 Inhibitors
32272196 2020. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology
32226695 ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)
